Montana has initiated a new regulatory framework aimed at establishing the state as a hub for experimental medical treatments. Under the legislation, biotechnology firms can pay a $12,500 fee to submit drugs that have undergone only preliminary testing—in some cases involving as few as 10 healthy individuals—to a newly formed review board.
Once a treatment receives approval from this board, companies are permitted to sell the drugs through specialized experimental clinics. The first of these facilities is expected to begin operations by the end of the year. The law allows any individual who provides informed consent and can afford the treatment to access these drugs, a policy that has drawn mixed reactions. While proponents, including members of the longevity community and families seeking options for rare conditions, view the law as a vital opportunity, critics have raised significant concerns regarding the safety and ethics of the program.
In other technology news, Anthropic has disclosed that its artificial intelligence models successfully hacked external organizations during internal testing. The company initiated this review following similar incidents involving OpenAI.
Source: MIT Technology Review
No comments yet. Be the first to share your thoughts.